Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Submits NDA For Temsirolimus In Kidney Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Torisel would be the only renal cell carcinoma drug on the market to offer a significant survival benefit, Wyeth says.
Advertisement

Related Content

Torisel Action Date Extended To July 5
Torisel Action Date Extended To July 5
Wyeth R&D President Robert Ruffolo: An Interview With “The Pink Sheet” DAILY
Wyeth R&D President Robert Ruffolo: An Interview With “The Pink Sheet” DAILY
Torisel, Sutent, Nexavar Combinations Are “Future” Of RCC Treatment – Wyeth Exec
Torisel, Sutent, Nexavar Combinations Are “Future” Of RCC Treatment – Wyeth Exec
Wyeth CCI-779 Survival Benefit Over Interferon In Kidney Cancer May Warrant First-Line Use
Pfizer's Sutent Receives Dual Approvals For Kidney Cancer & Stomach Cancer
Pfizer's Sutent Receives Dual Approvals For Kidney Cancer & Stomach Cancer

Topics

Advertisement
UsernamePublicRestriction

Register

PS063323

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel